Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs GSK plc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.85, while GSK plc trades at $50.35 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Global X Robotics and Artificial Intelligence ETF pays none. Which is the better fit depends on your goals.
| BOTZ | GSK | |
|---|---|---|
52-Week High | $41.63 | $61.18 |
52-Week Low | $31.99 | $38.22 |
Market Cap | — | $102.60B |
Sector | — | Health |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.85, up 1.15% today, with a bullish technical signal from moving averages. The ETF's RSI levels suggest overbought conditions, while ADX indicates a strong trend. Recent news highlights its role in robotics and AI investing, with a focus on global tech exposure beyond U.S. markets.
Outlook remains positive due to thematic growth in robotics and AI, supported by institutional interest. Risks include sector volatility and competition from other ETFs. The dividend of $0.02 scheduled for July 2026 adds income appeal, but valuation metrics are unavailable for deeper analysis.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
